Accurate identification of ALK fusion variants is essential for identifying NSCLC patients likely to benefit from ALK inhibitor therapy; for example, KIF5B‐ALK–positive NSCLC patients often respond favorably to ALK TKIs, including crizotinib [31, 32]. This evidence concerns the gene KIF5B and non-small cell lung carcinoma.